Our group focuses on developing targeted therapies for rare immunological conditions, such as primary immunodeficiency diseases and immunological conditions of unknown origin.
We aim to optimize the CRISPR-Cas gene editing technology as a gene therapy in these diseases, and stratify the existing therapies – such as biologic drugs and small molecule inhibitors – to better target the underlying molecular pathways that malfunction in individual patients.
We utilise custom genomics and high-throughput screening to understand immune diseases and optimize CRISPR-Cas9 genome editing towards safe and efficient use in patients. We work with cell models and patient material.
Our international team is based at the Centre for Molecular Medicine Norway in Oslo, Norway. We have diverse backgrounds and expertise in biosciences and clinical medicine.
Our main projects involve optimising genome editing, along with personalised use of targeted therapies in rare diseases. We’re interested in rare and undiagnosed immunological diseases.
See our latest studies and research highlights in genome editing and novel genetic etiologies of immunological diseases in chronological order.
We are working on editing defective genes with CRISPR, a method we hope can cure all primary immunodeficiency diseases in the future. The technique we
Thapelo is back with us to work on his master’s thesis, and Carolina has joined the team as our new PhD student. Welcome!
We’ve received a 19.9 million NOK funding from KLINBEFORSK for developing CRISPR-Cas9 gene therapy for STAT1 Gain-of-Function disease.
